Advertisements



We are Sorry, This Page doesn't Exist


Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatiti.....»»

Category: personnelSource: nytMay 16th, 2018

Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus. Roche RHHBY announced encouraging data from the final analysis of the CLL11 study, evaluating Gazyva-based treatment in previously untreated.....»»

Category: smallbizSource: nytJun 15th, 2018

Allergan (AGN) Presents Positive Data on Glaucoma Candidate

Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular.....»»

Category: worldSource: nytJun 14th, 2018

GSK two-drug HIV regimen meets primary endpoint in Phase III study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2018

Pluristem reports "positive" results from Phase II clinical study of PLX-PAD

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2018

Alnylam Reports Positive Data on Lumasiran in Renal Disease

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients. Alnylam Ph.....»»

Category: smallbizSource: nytJun 11th, 2018

Proteostasis announces "positive" results from Phase 1 Study of PTI-801

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 6th, 2018

Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia. Inovio Pharmaceuticals, INO has initiated a .....»»

Category: dealsSource: nytMay 22nd, 2018

Nabriva Therapeutics unveils positive results in bacterial pneumonia drug trial

Nabriva Therapeutics PLC on Monday reported positive results in a a late-stage trial of a treatment for bacterial pneumonia, saying the phase 3 trial of Lefamulin Evaluation Against Pneumonia (LE.....»»

Category: topSource: marketwatchMay 21st, 2018

VBI Vaccines announces "positive" final Phase 1 study results for VBI-1501

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018

Alnylam announces alignment with FDA on Phase 3 study for lumasiran

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 3rd, 2018

Esperion Shares Plunge After Cholesterol-Lowering Drug"s Phase 3 Results Stir Safety Concerns

Esperion Therapeutics Inc (NASDAQ: ESPR) shares are in free fall Wednesday after the company repor.....»»

Category: earningsSource: benzingaMay 2nd, 2018

Esperion Shares Plunge After Cholesterol-Lowering Drug"s Phase 3 Results Stir Safety Concerns

Esperion Therapeutics In.....»»

Category: blogSource: benzingaMay 2nd, 2018

Esperion shares halted on positive late-stage trial results

Esperion Therapeutics Inc. shares were halted in premarket trade Wednesday on news of positive results for a late-stage clinical trial of its cholesterol-lowering medication. The phase 3 trial, which enrolled .....»»

Category: topSource: marketwatchMay 2nd, 2018

Why Karyopharm Is on the Move

Karyopharm Therapeutics saw its shares make a handy gain on Tuesday after the firm announced positive top-line results from the Phase 2b STORM study evaluating selinexor......»»

Category: blogSource: 247wallstMay 1st, 2018

Catalyst Enrolls First Patient in Phase III Firdapse Study

Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis. Catalyst Pharmaceuticals, Inc. CPRX, enroled.....»»

Category: worldSource: nytApr 20th, 2018

Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of a.....»»

Category: worldSource: nytApr 17th, 2018

Therapix Biosciences up 36% after positive results from Phase 2 THX-110 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 9th, 2018

Merck"s stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»

Category: topSource: marketwatchApr 9th, 2018

AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial

Shares of AbbVie Inc. jumped 2.2% in premarket trade Monday, after the company reported positive results in a late-stage trial of a treatment for rheumatoid arthritis. AbbVie said the phase 3 trial of upadacitinib met its primary endpoints. Upadaciti.....»»

Category: topSource: marketwatchApr 9th, 2018